A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Findings of study demonstrating the effectiveness of combining bimagrumab – a drug designed to combat muscle loss – with a common GLP-1 receptor agonist (RA), semaglutide, were presented ...

While GLP-1 drugs' effects on metabolism are best known, basic studies have shown that inflammatory and neurological pathways may be affected as well, either directly or as a consequence of the ...

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity.

LA-GLP1 RA Effects on the Risk of Medullary Thyroid Cancer GLP-1 receptors are present in several tissues including the pancreas, intestine, stomach, nervous system and others.

Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeysBMF-650 compared favorably to published data of a leading GLP-1 RA candidateIND ...

All told, who took GLP-1 receptor agonists had a 7% lower risk of developing an OAC – which include cancers of the oesophagus, colon, rectum, stomach, liver, gallbladder, pancreas, kidney, post ...